Maximizing Return on Socioeconomic Investment in Phase II Proof-of-Concept Trials
Authors:
- 31 March 2014
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 20 (7) , 1730-1734
Abstract
Phase II proof-of-concept (POC) trials play a key role in oncology drug development, determining which therapeutic hypotheses will undergo definitive phase III testing according to predefined Go-No Go (GNG) criteria. The number of possible POC hypotheses likely far exceeds available public or private resources. We propose a design strategy for maximizing return on socioeconomic investment in phase II trials that obtains the greatest knowledge with the minimum patient exposure. We compare efficiency using the benefit–cost ratio, defined to be the risk-adjusted number of truly active drugs correctly identified for phase III development divided by the risk-adjusted total sample size in phase II and III development, for different POC trial sizes, powering schemes, and associated GNG criteria. It is most cost-effective to conduct small POC trials and set the corresponding GNG bars high, so that more POC trials can be conducted under socioeconomic constraints. If δ is the minimum treatment effect size of clinical interest in phase II, the study design with the highest benefit–cost ratio has approximately 5% type I error rate and approximately 20% type II error rate (80% power) for detecting an effect size of approximately 1.5δ. A Go decision to phase III is made when the observed effect size is close to δ. With the phenomenal expansion of our knowledge in molecular biology leading to an unprecedented number of new oncology drug targets, conducting more small POC trials and setting high GNG bars maximize the return on socioeconomic investment in phase II POC trials. Clin Cancer Res; 20(7); 1730–4. ©2014 AACR.Keywords
This publication has 10 references indexed in Scilit:
- Evaluation of Early Efficacy Endpoints for Proof-of-Concept TrialsJournal of Biopharmaceutical Statistics, 2013
- Optimal Strategies for Developing a Late-Stage Clinical Program With a Possible Subset EffectStatistics in Biopharmaceutical Research, 2012
- Integrating predictive biomarkers and classifiers into oncology clinical development programmesNature Reviews Drug Discovery, 2011
- Hypothesis Testing in a Confirmatory Phase III Trial With a Possible Subset EffectStatistics in Biopharmaceutical Research, 2009
- Optimal Cost-Effective Go-No Go Decisions in Late-Stage Oncology Drug DevelopmentStatistics in Biopharmaceutical Research, 2009
- Optimal Cost-Effective Designs of Phase II Proof of Concept Trials and Associated Go–No Go DecisionsJournal of Biopharmaceutical Statistics, 2009
- Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line ChemotherapyJournal of Clinical Oncology, 2007
- Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized TrialsJournal of Clinical Oncology, 2005
- Participation in Cancer Clinical TrialsJAMA, 2004
- Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort StudyJournal of Clinical Oncology, 2002